ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 14, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 14, 2011
News
FDA Introduces Strategy to Combat Food Smuggling
By Angie Drakulich
FDA announced in early July 2011 that it has made progress toward implementing the US Food Safety Modernization Act, which was enacted in January of this year.
SOCMA Offers Support for Free Trade Pacts with South Korea, Panama, and Colombia
By Patricia Van Arnum
SOCMA has issued its support this week of the passage of pending free-trade agreements with South Korea, Panama, and Colombia by two Congressional committees.
FDA Bans Import of Drugs from Dr. Reddy's Mexico Site
By Erik Greb
FDA banned the importation of products manufactured at the Mexican unit of Dr. Reddy's Laboratories. The import ban is a result of the company's failure to correct the violations listed in a recent Warning Letter to the agency's satisfaction.
The Economic Contribution of the US Biopharmaceutical Industry
By Amy Ritter
Recent trends in the US biopharmaceutical industry suggest this is a pivotal area for potential job creation.
EMA Plans Public Access to Side-Effects Data
By Stephanie Sutton
Members of the public will soon be able to access data in the EudraVigilance database—EMA's central repository for reports of suspected adverse reactions related to authorized medicines in the European Economic Area.
Week of July 11, 2011: UPS and Merck Extend Distribution and Logistics Agreement; Merck Serono Makes Two Executive Management Team Appointments; and More.
Sanofi Forms Research Pact with Weill Cornell Medical Center; Steven A. Nichtberger Resigns as President and CEO of Tengion; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here